Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Glumetinib (SCC244) | 99.87%(HPLC) | In Stock | c-Met inhibitor
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
APExBIO - PHA-665752|C-Met inhibitor,potent and ATP-competitive|CAS# 477575-56-7